Skip to main content
Premium Trial:

Request an Annual Quote

Ipsogen Licenses Mutation from French Institutes for Myeloproliferative Disorders

NEW YORK, March 30 (GenomeWeb News) - Ipsogen has obtained an exclusive worldwide license from three French institutions to a mutation in the JAK2 gene believed to enable researchers to better classify myeloproliferative disorders, the company said today.

 

It licensed the mutated tyrosine kinase from the Institut Gustave Roussy, the French National Health and Medical Research Institute, and Assistance Publique-Hôpitaux de Paris.

 

If used as a biomarker, the mutation can provide information about the nature of an elevated platelet or red blood cell count, which occurs frequently. Ipsogen said it is developing a "decentralized" CE marked test that will integrate the company's FusionQuant and ProfileQuant technologies.

 

Financial terms of the agreement were not disclosed.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more